Back to top
more

STERIS (STE)

(Delayed Data from NYSE)

$225.18 USD

225.18
487,798

+3.33 (1.50%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $225.18 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Urmimala Biswas headshot

MedTech M&A Scaling New Heights in 2021 on Rising Investor Wealth

While smaller tuck-in acquisitions dominated the M&A space throughout 2020, 2021 is seeing a number of colossal deals.

Here's Why You Should Hold on to STERIS (STE) Stock Now

Investors are optimistic about STERIS (STE) owing to strong segmental performance amid the pandemic and huge growth potential in healthcare and pharmaceutical industries.

Steris (STE) Down 6.1% Since Last Earnings Report: Can It Rebound?

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q3

STERIS' (STE) third-quarter fiscal 2021 results reflect strong performance by all three of its reporting segments despite the coronavirus-led economic crisis.

Steris (STE) Q3 Earnings and Revenues Surpass Estimates

Steris (STE) delivered earnings and revenue surprises of 10.90% and 1.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

MedTech Stock Earnings on Feb 2: IDXX, MCK & More

In Q4, MedTech stocks are expected to have gained from month-wise sales rebound in many states and regions. However, international sales might have been dampened.

STERIS (STE) to Report Q3 Earnings: What's in the Cards?

Within Life Sciences, STERIS (STE) might have registered benefits from pharma customers on growing vaccines, along with a recovery in the Healthcare arm in Q3.

Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STERIS (STE) to Expand Product Suite Via Cantel Medical Buyout

STERIS (STE) expects to strengthen and expand its endoscopy offerings along with extending into a new customer territory via the Cantel Medical buyout.

Why Is Steris (STE) Up 10% Since Last Earnings Report?

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Industry Outlook Highlights: ResMed, Thermo Fisher Scientific, IDEXX Laboratories and STERIS

Zacks Industry Outlook Highlights: ResMed, Thermo Fisher Scientific, IDEXX Laboratories and STERIS

Urmimala Biswas headshot

3 Best Buys from the Prospering Medical Instruments Industry

Despite the challenges posed by the COVID-19 pandemic, higher demand for lab-testing products, digital influence, and AI and robotics is likely to lend support to the Zacks Medical - Instruments industry. TMO, IDXX and STE are well positioned to gain.

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q2

STERIS' (STE) second-quarter fiscal 2021 results reflect strong performance by the Life Sciences and the Applied Sterilization Technologies segments despite the coronavirus-led economic crisis.

Steris (STE) Q2 Earnings and Revenues Surpass Estimates

Steris (STE) delivered earnings and revenue surprises of 19.35% and 7.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Earnings Due on Nov 2: STE, HSIC & More

Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. Let's see how STE, HSIC, PACB, INSP are poised ahead of their announcements.

STERIS (STE) to Report Q2 Earnings: What's in the Cards?

Within Life Sciences, STERIS (STE) might have registered benefit from pharma customers on growing vaccines and biologics businesses in Q2.

Analysts Estimate Steris (STE) to Report a Decline in Earnings: What to Look Out for

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Steris (STE) Hits Fresh High: Is There Still Room to Run?

Steris (STE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

STERIS (STE) Hits a New 52-Week High: What's Driving It?

STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with strength in its Life Sciences business.

Steris (STE) Up 0.5% Since Last Earnings Report: Can It Continue?

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q1

STERIS' (STE) first-quarter fiscal 2021 results reflect strong performance by the Life Sciences segment despite the coronavirus-led economic crisis.

Steris (STE) Beats Q1 Earnings and Revenue Estimates

Steris (STE) delivered earnings and revenue surprises of 35.05% and 4.55%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

STERIS (STE) to Report Q1 Earnings: What's in the Cards?

STERIS (STE) registers declines in Healthcare Products with neutral performance in Life Science and AST in April, which is likely to have impacted Q1 earnings.

Analysts Estimate Steris (STE) to Report a Decline in Earnings: What to Look Out for

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STERIS (STE) Segmental Growth Robust Amid Coronavirus Woes

As a major landmark for STERIS (STE), in fiscal 2020, the company joined the coveted S&P 500 Index.